Biennial Miami Precision Medicine Conference

Craig H. Moskowitz, MD, discussed the transition toward molecularly defined lymphoma care and the declining role of autologous stem cell transplantation.

Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.

Presenters at the 3rd Biennial Miami Precision Medicine 2026 Conference shared insights related to pancreatic cancer, sarcomas, and genitourinary diseases.

Although ctDNA has limited utility in well-differentiated disease, it may have use in monitoring molecular residual disease in high-grade carcinomas.

Making pancreatic cancer an immunotherapy-receptive disease requires identifying select patient subgroups who may benefit.

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

An analysis conducted by Starr and associates showed that patients with high disease burden in the liver did not experience liver failure with PRRT.

Microsatellite instability-high status may make patients suitable candidates to receive agents like pembrolizumab, according to Steven Bialick, DO.